Ossirene AS101|cas:106566-58-9|西域试剂

Ossirene AS101,98.0%

产品编号：Bellancom-101019| CAS NO：106566-58-9| 分子式：C₂H₈Cl₃NO₂Te| 分子量：312.05

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-101019		￥3500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Ossirene AS101

产品介绍

Ossirene (AS101) 是一种免疫调节性碲化合物，有效的 IL-1β 抑制剂。Ossirene 通过抑制 IL-10 消除 STAT3 的磷酸化。Ossirene 有效抑制 Caspase-1，可用于自身免疫性疾病和某些恶性肿瘤。

生物活性

Ossirene (AS101), an immunomodulatory tellurium compound, is a potent IL-1β inhibitor. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene potently inhibits Caspase-1 and is used for the autoimmune diseases and certain malignancies^[4].

体外研究

Ossirene (AS101; 1 μg/mL; for 24 hours) almost completely abrogates expression of pStat3. Ossirene may reduce expression of Bcl-2 after inhibition of Stat3 activation via IL-10 inhibition.
AS101 (0.5, 5 mg/mL; 24 hours) inhibits IL-1β-induced mRNA expression of inflammatory mediators in the RPE in a dose-dependent manner. AS101 inhibits IL-1β-induced mRNA expression and protein production of IL-6 and IL-8 in RPE cells. AS101 (5 mg/mL; 1 hour) inhibits the phosphorylation of the p65 component of the NFκB complex activated by IL-1β.
Ossirene (0.1, 0.5, 1, 2.5 μg/mL) significantly decreases B16 melanoma, stomach adenocarcinoma, and human glioblastoma multiforme (GBM) cells proliferation.
AS101 (0.5 μg/mL; for 24 hours) sensitizes GBM tumor cells to paclitaxel in an IL-10-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	B16 melanoma cells
Concentration:	1 μg/mL
Incubation Time:	For 24 hours
Result:	Almost completely abrogated expression of pStat3.

RT-PCR

Cell Line:	ARPE19 cells
Concentration:	0.5, 5 mg/mL
Incubation Time:	24 hours
Result:	Inhibited IL-1β-induced mRNA expression of inflammatory mediators in the RPE in a dose-dependent manner.

体内研究
(In Vivo)

Ossirene (AS101; 0.5 mg/kg/day; IP; 25 days) sensitizes GBM tumors to paclitaxel via inhibition of IL-10, resulting in increased survival.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice with GBM cells
Dosage:	0.5 mg/kg
Administration:	IP; daily; 25 days
Result:	Significantly increased survival of GBM tumor-bearing mice.

体内研究

Ossirene (AS101; 0.5 mg/kg/day; IP; 25 days) sensitizes GBM tumors to paclitaxel via inhibition of IL-10, resulting in increased survival.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice with GBM cells
Dosage:	0.5 mg/kg
Administration:	IP; daily; 25 days
Result:	Significantly increased survival of GBM tumor-bearing mice.

体内研究

Ossirene (AS101; 0.5 mg/kg/day; IP; 25 days) sensitizes GBM tumors to paclitaxel via inhibition of IL-10, resulting in increased survival.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice with GBM cells
Dosage:	0.5 mg/kg
Administration:	IP; daily; 25 days
Result:	Significantly increased survival of GBM tumor-bearing mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 12.5 mg/mL (40.06 mM; ultrasonic and warming and heat to 80°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2046 mL	16.0231 mL	32.0461 mL
5 mM	0.6409 mL	3.2046 mL	6.4092 mL
10 mM	0.3205 mL	1.6023 mL	3.2046 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 1.25 mg/mL (4.01 mM); Suspended solution; Need ultrasonic

此方案可获得 1.25 mg/mL (4.01 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 1.25 mg/mL (4.01 mM); Suspended solution; Need ultrasonic

此方案可获得 1.25 mg/mL (4.01 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.25 mg/mL (4.01 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (4.01 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。